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Severity of disease is markedly increased when infec-
tion with dengue virus type 2 (DENV-2) follows infection
with DENV-1 at an interval of 20 years. Studies have shown
that heterologous neutralizing antibody titers are inversely
correlated with severity of a second infection. If this mech-
anism controlled disease severity in Cuba, heterotypic anti-
body titers should have declined over time. To determine
whether phenotypic changes in dengue antibodies occur
over time, we analyzed serum samples collected 4–8 and
20–22 years after DENV-1 infection. We found a significant
increase in mean titer of homologous DENV-1 neutralizing
antibodies and a significant decrease in heterologous anti-
bodies to 1 of 2 genotypes of DENV-2 virus (the American
genotype). Asian DENV-2 viruses were not neutralized dur-
ing either interval; however, the American genotype under-
went phenotypic changes in heterotypic viral neutralizing
antibodies in the predicted direction. This finding may be
related to the time-dependent changes in severity of dis-
ease found with secondary dengue infection.
D
uring 1977, Cuba experienced a nationwide outbreak
of dengue fever (DF). More than 500,000 cases
caused by a dengue 1 virus (DENV-1) of Southeast Asian
origin were reported (1,2). Seroepidemiologic studies dur-
ing 1978–1979 demonstrated hemagglutination-inhibition
antibodies against dengue virus in 44.46% of the popula-
tion (1). In 1981, an Asian genotype dengue 2 (DENV-2)
produced a major islandwide epidemic of DF and dengue
hemorrhagic fever (DHF); >400,000 cases were reported,
10,000 of which resulted in DHF and 158 deaths (101
children) from DHF (3–8). During 1982–1996, strong
vector-control programs stopped transmission of dengue
viruses.
In 1997, an Asian genotype DENV-2, closely related
to the 1981 strain, entered Cuba and circulated in the
island’s second largest city, Santiago de Cuba, producing a
severe outbreak of DF and DHF (9,10). At the time of the
outbreak, 25%–35% of the population 18–54 years of age
were monotypically immune to DENV-1 because of infec-
tions during 1977–1979 (1,2,11). During the 1997 epidem-
ic, an estimated 4,810 adults experienced a second dengue
infection with DENV-2, 18–20 years after infection with
DENV-1 (10). Of this group, 205 patients were hospital-
ized with DHF, 12 of whom died. No cases of DHF or
dengue shock syndrome were observed in children (12).
When standardized for age, case-fatality rates for persons
who had been infected with DENV-1 during 1977–1979
and secondarily infected with DENV-2 in 1997 were 3–4×
higher than for persons who had secondary DENV-2 infec-
tions in 1981 (13). In addition, virtually all (≈100%) sec-
ondary DENV-2 infections in the 1997 Santiago de Cuba
outbreak were clinically overt in marked contrast to pri-
mary DENV-2 infections, of which only 3.0% produced
overt disease (10).
Both DENV-2 viruses, from 1981 and 1997, belong to
the same genotype. Although amino acid differences in
structural and nonstructural regions of the 2 genomes
might contribute to the observed differences in disease
severity, the low intrinsic virulence of the 1997 DENV-2
virus was remarkable. In this study, we focused on the pos-
sibility that presence or absence of heterotypic neutralizing
antibodies might contribute to severity of secondary
DENV-2 infections. 
Several observations suggest this to be a mechanism
for controlling dengue disease severity during heterotypic
infections. The first such observations were made by
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Sabin, who observed a 3-month period of cross-protection
to DENV-2 illnesses after DENV-1 infections in human
volunteers (14). When DENV-1–immune volunteers were
challenged with DENV-2 at intervals >3 months, classical
DF occurred. A comparable observation was made in a
school-based study in Thailand (15), in which 40 children
experienced predominantly secondary DENV-2 infections;
of these, 33 were fully protected from disease accompany-
ing DENV-2 infections and only 7 were hospitalized. Of
the former, human monocyte assay of undiluted serum
showed that 31 had DENV-2 neutralizing antibodies from
a prior heterotypic dengue infection. By contrast, serum
from 6 children who had severe disease did not have neu-
tralizing antibodies, but it enhanced DENV-2 infections
(15). A similar observation was made in Iquitos, Peru,
where DENV-1 had been endemic since 1990. In 1995, an
American genotype DENV-2 was introduced into this pop-
ulation that was already highly immune to DENV-1 (16).
Despite large numbers of persons who were infected ini-
tially with DENV-1 and subsequently with DENV-2, no
DHF cases were observed. Plaque-reduction neutralization
test (PRNT) of DENV-1–immune human serum samples
obtained in 1994 in Iquitos showed that nearly all con-
tained high levels of neutralizing antibodies to American
genotype but not Asian genotype DENV-2 viruses. The lat-
ter viruses have circulated for a long time in populations
who are immune to multiple dengue viruses and who could
plausibly have lost DENV-1–like epitopes by preferential
selection of antibody escape mutants (17). 
Thus, from these 2 studies we deduced that cross-reac-
tive, dengue-neutralizing antibodies may down-regulate
secondary dengue infections and prevent enhanced infec-
tions while mediating disease in persons with a different
immune status. These observations are supported by recent
studies in which DENV-1–immune monkeys were chal-
lenged with either American or Asian DENV-2 (18). On
the basis of these observations, we examined whether
dengue antibodies undergo phenotypic changes after many
years; such changes would help explain the observed




Serum samples were submitted to our laboratory from
a nationwide dengue surveillance program implemented
during 1981–1985 (103 samples) and 1999 (2,000 sam-
ples). ELISA results showed no evidence of acute dengue
infection. To avoid analyzing serum from persons infected
by any other DENV, we excluded samples from Santiago
de Cuba province because of the DENV-2 epidemic that
occurred in 1997 (19,20).
Serum samples were first tested for dengue
immunoglobulin G (IgG) by an ELISA inhibition method
that used a DENV-1 antigen shown to provide the same or
better sensitivity and specificity as tests that use all 4
dengue viruses. Samples with dengue IgG were retested by
PRNT, which used strains of the 4 dengue serotypes,
including 2 DENV-2 strains classified as either Asian
(3,4,8) or American genotype (21) (Table 1). Testing for all
dengue viruses by PRNT was conducted on BHK-21,
clone 15 cells (22,23). Serum was diluted to 1:10, and then
serial 10-fold dilutions were made in Earle’s minimal
essential medium (MEM). To obtain 15–20 plaques in a
24-well tissue culture plate, we mixed 100 µL of each
serum dilution with 100 µL of media containing 80 PFUs
of the assayed viruses and incubated this mixture at 37°C
for 1 h. Then 50 µL of virus-serum mixture was added in
triplicate onto 0.5 mL media containing 2.5 × 105 cells.
After incubating this mixture for 4 h at 37°C in an atmos-
phere of 4.5% CO2, we added 0.5 mL of overlay medium
that contained 3% medium viscosity carboxymethylcellu-
lose prepared in MEM without phenol red with 10% heat-
inactivated fetal bovine serum, 1% glutamine (2 mmol/L),
100 U penicillin, and 100 µg/mL streptomycin. Infected
cells were incubated for 5–9 d, depending on the virus
serotype (7–9 d for DENV-1 and DENV-3, 5 d for DENV-
2, and 6 d for DENV-4), under the same conditions. After
incubation, plates were stained with a solution of naphthol
blue-black dye and acetic acid, and the plaques were
counted. Serum samples were tested simultaneously
against each DENV strain; each serum dilution was tested
in triplicate. 
Antibody titers were expressed as the reciprocal of the
endpoint dilution. For statistical purposes, samples with a
titer <10 were assigned a titer of 5. Calculations of 50%
endpoint plaque-reduction neutralization titers (PRNT50)
were made by using log probit paper and the method of
Russell et al. (24). According to criteria previously estab-
lished (25), samples with neutralizing antibody titers ≥30 to
only 1 dengue virus were considered evidence of primary
dengue infection. Considering the epidemiology of dengue
in Cuba and using the DENV-2 strain that circulated during
the 1981 epidemic, we classified samples that had dengue
neutralizing antibodies >30 to DENV-1 but <5 for DENV-
2 (A15/81 strain), DENV-3, and DENV-4 as a past primary
DENV-1 infection during the 1977–1979 epidemic.
Statistical Analysis
For data analysis, we used GraphPad Prim 2.0 (SPSS
Inc., Chicago, IL, USA). Neutralizing antibody titers were
expressed as mean titers. Mean titers were compared to
detect significant differences between antibody titers to
viruses in each studied group and in both groups of
samples by using 1-way analysis of variance followed by
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icance was defined as p<0.05. The Fisher exact test was
used to compare the positive percentages of neutralizing
antibody to each virus in each group of samples.
Results
Of the 103 serum samples collected during
1981–1985 and the 2,000 collected in 1999, dengue IgG
antibodies were detected by screening ELISA inhibition
method in 50 (48.5%) and 826 (41.3%), respectively. From
these, the 50 samples in the first group (group 1) and 89
representative samples from the second (group 2) were
classified as monotypic DENV-1–immune serum on the
basis of PRNT50 results with the 4 dengue serotypes.
Table 2 shows that the geometric mean titer of homol-
ogous neutralizing antibodies increased significantly in
samples collected after 22 years compared with those col-
lected 4–8 years after the DENV-1 epidemic of 1977. In
contrast, over this same period, heterotypic antibodies
directed against the American genotype of DENV-2
declined significantly in the number of samples that had
heterotypic neutralizing antibodies to this genotype and in
geometric mean titer. DENV-1–immune serum obtained
years after inapparent infection showed little heterotypic
neutralization of Asian DENV 2 (12%), DENV-3 (8%), or
DENV-4 (2%) viruses.
The Figure shows each data point, together with mean
log10 neutralizing antibody titers to the viruses tested in the
studied groups. Means of DENV-1 antibodies differed sig-
nificantly between groups 1 and 2. Means of antibody
titers were significantly different (p<0.001) when DENV-
2 (I/348600) was compared with DENV-3 and DENV-4
viruses. Significant differences (p<0.001) were also noted
in heterotypic neutralization of DENV-2 (I/348600) in
samples from groups 1 and 2. Means of DENV-2 (A
15/81), DENV-3, and DENV-4 did not differ between
groups 1 and 2.
Discussion
We present 2 new findings. After DENV-1 infection,
homotypic neutralizing antibody titers increase, and het-
erotypic antibody titers to 1 of 2 genotypes of DENV-2
virus (the American genotype) decrease.
However, our study had several limitations. One
problem was that limited serum quantities precluded our
ability to test for neutralization and enhancement in pri-
mary cultures of human monocytes. Another problem was
that the effect of heterotypic neutralizing antibodies on the
severity of DENV-2 infections during the 1981 epidemic
should have been studied in a representative selection of
samples collected before the 1981 outbreak from persons
infected by DENV-1 during 1977–1979. Long-term kinet-
ics of neutralizing antibodies requires that samples be col-
lected at intervals from the same persons. To compensate
for our inability to conduct longitudinal studies with the
same persons, we studied relatively large numbers of sam-
ples from randomly selected persons who were immune to
DENV-1. Serum available for study was sent to our diag-
nostic laboratory over a period of many years and stored
at –20°C. Samples were sent from representative age and
ethnic groups from all geographic areas of Cuba, exclud-
ing Santiago de Cuba province. We provide independent
confirmation of the cross-neutralization of American
genotype DENV-2 by antibodies raised to DENV-1 infec-
tions in Cuba.
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a decrease in heterotypic DENV-2 neutralizing antibodies
over time. Like Kochel et al. (17), we were unable to detect
significant heterotypic neutralization to the Asian geno-
type DENV-2 viruses. We did not observe increases in het-
erotypic DENV-3 or DENV-4 antibody titers.
Unexpectedly, we did observe an increase in titer of
homologous DENV-1 antibodies at 4–8 and 20–22 years
after infection.
Although we did not detect significant heterotypic neu-
tralization of the A15/81 Asian DENV-2 strain at a 1:10
dilution, these results do not rule out the possibility that
neutralization might have been detected at lower dilutions.
Limited serum volumes prevented us from testing the panel
of DENV-1–immune serum collected during 1981–1985
for heterotypic neutralizing antibodies to the 1997 DENV-
2 strain (58/97) isolated during the 1997 Santiago de Cuba
epidemic and classified as Asian genotype (9). However,
we did test group 2 serum (collected in 1999). No differ-
ences were observed in neutralization of the A15/81 or
58/97 DENV-2 strains by DENV-1–immune serum at a
dilution of 1:10. Only 18% of group 2 samples showed neu-
tralizing activity to the 58/97 DENV-2 strain with a geo-
metric mean titer of 7.1. We believe the antibodies
measured in the 2 groups were derived from infections that
occurred in Cuba in 1977. Among persons who contributed
to each group of serum samples, none had been vaccinated
against yellow fever and few had traveled outside Cuba.
Our results demonstrate long-term changes in het-
erotypic dengue neutralizing antibodies. Although we did
not detect neutralization of Asian DENV-2 in vitro, we
question whether some degree of neutralization might
have occurred in vivo, which might have affected disease
severity. For example, the neutralization test is not partic-
ularly good at predicting protective immunity. Recently,
Endy et al. (26) reported that levels of preinfection neutral-
izing antibodies against DENV-2 (standard strain and virus
isolated during illness) were not associated with severity of
secondary DENV-2 infection. However, in the same study,
higher levels of preexisting neutralizing antibodies against
DENV-3 were associated with lower viremia levels and
milder disease. Many possible reasons exist for these com-
plexities, including the artificiality of existing dengue viral
neutralization tests or differences in ability of antibodies to
neutralize different dengue strains of the same genotype.
The first report that heterotypic neutralizing antibod-
ies might be an important mechanism of down-regulating
the severity of dengue infection was deduced from the
prospective study of school children in Bangkok, Thailand.
Children who had heterotypic DENV-2 neutralizing anti-
bodies before they became infected with DENV-2 (their
antibodies were predominantly the result of prior DENV-1
infections) experienced only inapparent secondary DENV-
2 infections. In contrast, DHF/dengue shock syndrome
developed in children whose serum lacked detectable het-
erotypic neutralizing antibodies (but contained dengue-
enhancing antibodies) (15). These studies tested undiluted
serum, before illness, in elutriated monocytes from donors
with no immunity to flaviviruses.
The contemporary explanation of long-term persist-
ence of antibodies after viral infection is based on evidence
of the presence of long-lived B memory and plasma cells.
The improvement in homotypic neutralizing antibody titer
and decrease in heterotypic neutralizing antibody titer
described here is reminiscent of affinity maturation.
However, long-lived plasma cells would not be expected to
participate in the selection process required for affinity
maturation. In an earlier study of serum samples from US
military personnel with inapparent Japanese encephalitis
virus infection, over the 1–5 years after infection, the log
neutralization index increased from a mean of 1.7 to 3.5
(27). This earlier study and our present study are unique in
that they measured qualitative attributes of human antibod-
ies for long intervals after infection with wild-type fla-
vivirus. Our preliminary data suggest a continuous process
of selection of populations of dengue virus antibodies with
increasing homologous reactivity and a concurrent
decrease in heterotypic cross-reactions.
Our results require confirmation and further study. To
study antibody titers in the same persons, we will attempt
to locate the persons from whom samples were collected
during 1981–1985 and collect serum in volumes that may
permit tests for dengue-enhancing antibodies and neutral-
izing antibodies to several dengue strains. Our present
results could simply reflect increases and decreases in
avidity of antibodies with the passage of time. We plan to
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Figure. Log10 antibody titers for human dengue virus type 1
(DENV-1)–immune serum samples collected in 1999 (89 samples)
and 1981–1985 (50 samples, mean).RESEARCH
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investigate this possibility by using the same strains as
well as a nondengue flavivirus antigen.
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